A man was killed Saturday afternoon when his motorcycle collided with another vehicle on U.S. 98 in the Bellevue community.

Rigel's dual IRAK 1/4 inhibitor program, as well as reduced trial activities related to the completed Phase 3 clinical trial of fostamatinib in patients with warm antibody hemolytic anemia (wAIHA).

Full Year 2024 Results Key Financial Results Revenue: US$179.3m (up 55% from ...

(AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported fourth-quarter earnings of $14.3 million. On a per-share basis, the South San Francisco ...

This represents a 3.82 % decrease in their position ... 9.04% of the stock is owned by company insiders. Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Shares of NASDAQ:RIGL opened at $22.33 on Friday. Rigel Pharmaceuticals has a 12-month low of $7.48 ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to ...